Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | LSS | P48449 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 2/20 | 0.35 |
| ▸ | F10 | P00742 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13621598 | 0.86 | F2 (0.39) | F2F10CA1CA2CA7 | |
| SCHEMBL13621597 | 0.85 | LSS (0.39) | LSSF2F10CA12CA1 | |
| SCHEMBL8247131 | 0.85 | LSS (0.39) | LSSF2F10CA12CA1 | |
| SCHEMBL5498879 | 0.85 | LSS (0.39) | LSSF2F10CA12CA1 | |
| SCHEMBL13621604 | 0.80 | LSS (0.36) | LSSF2F10CA12CA1 | |
| SCHEMBL13621609 | 0.80 | LSS (0.36) | LSSF2F10CA12CA1 | |
| SCHEMBL13632161 | 0.80 | LSS (0.35) | LSSF2F10CA12CA1 | |
| SCHEMBL13632157 | 0.80 | LSS (0.35) | LSSF2F10CA12CA1 | |
| SCHEMBL13621595 | 0.80 | LSS (0.35) | LSSF2F10CA12CA1 | |
| SCHEMBL13621603 | 0.76 | EPHX2 (0.40) | LSSCA12ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286837-A1 | Oxadiazole compounds as urokinase inhibitors | WILEX AG (DE) | 2009-11-19 | — | — | US | disclosed |
| US-20090286837-A1 | Oxadiazole compounds as urokinase inhibitors | WILEX AG (DE) | 2009-11-19 | — | — | US | disclosed |
| WO-2007025718-A1 | OXADIAZOLE COMPOUNDS AS UROKINASE INHIBITORS | WILEX AG (DE) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286837-A1 | Oxadiazole compounds as urokinase inhibitors | PLAUR, PLAU, PLAT | CNR1 2760/4885CNR2 2890/4885LSS 3492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.